(TRIAL ONGOING) This clinical trial, that commenced on 1 April 2020, is trialling HBOT-treatment for 48 COVID-19 positive patients. Participants are randomized into HBOT treatment group vs control group. Both groups are receiving same inpatient medical treatment. The primary outcome of this study measures the decrease of incidents of intubation by 30% or greater and incidents of renal injury during the one month duration of the HBOT treatment cycle. After completion of the treatment protocol, specific study endpoints are being compared between the two groups. The biostatistician and radiologist are at no time informed which group receive HBOT.